Compare COFS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | FULC |
|---|---|---|
| Founded | 1898 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 467.8M |
| IPO Year | 1995 | 2019 |
| Metric | COFS | FULC |
|---|---|---|
| Price | $34.15 | $3.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $34.00 | $16.38 |
| AVG Volume (30 Days) | 106.1K | ★ 3.1M |
| Earning Date | 04-24-2026 | 04-27-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $227,624,000.00 | N/A |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $37.30 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $2.83 |
| 52 Week High | $34.90 | $15.74 |
| Indicator | COFS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 43.40 |
| Support Level | $29.98 | $3.41 |
| Resistance Level | $34.90 | $4.02 |
| Average True Range (ATR) | 0.98 | 0.19 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 63.18 | 58.59 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.